Cargando…

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition

Detalles Bibliográficos
Autores principales:	Ottaiano, Alessandro, Capuozzo, Maurizio, Nasti, Guglielmo, Maiolino, Piera, De Angelis, Valentina, Scala, Stefania, Iaffaioli, Rosario V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539668/ https://www.ncbi.nlm.nih.gov/pubmed/23316197 http://dx.doi.org/10.3389/fimmu.2012.00409

Ejemplares similares

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome
por: Calemma, Rosa, et al.
Publicado: (2012)

Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review
por: Santorsola, Mariachiara, et al.
Publicado: (2022)

Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Etanercept induces remission of polyarteritis nodosa: a case report
por: Capuozzo, Maurizio, et al.
Publicado: (2014)

Epidemiology and Economic Impact of Celiac Disease in the South Vesuvian Area of Naples: A Survey
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2018)

Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Nilotinib for the Frontline Treatment of Chronic Myeloid Leukemia Carrying the p230 Transcript: Dream or Reality?
por: Capuozzo, Maurizio, et al.
Publicado: (2014)

KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology
por: Capuozzo, Maurizio, et al.
Publicado: (2022)

Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples
por: Capozzi, Monica, et al.
Publicado: (2018)

Hypertension, type 2 diabetes, obesity, and p53 mutations negatively correlate with metastatic colorectal cancer patients’ survival
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer
por: D’Alterio, Crescenzo, et al.
Publicado: (2020)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

BRAF p.V600E mutation as a molecular boundary between genuine oligo-repeated and poly-metastatic disease in colorectal cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2023)

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy
por: Ottaiano, Alessandro, et al.
Publicado: (2017)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment
por: Barbieri, Antonio, et al.
Publicado: (2017)

Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2020)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

p53: From Fundamental Biology to Clinical Applications in Cancer
por: Capuozzo, Maurizio, et al.
Publicado: (2022)

Current concepts of anti-EGFR targeting in metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2022)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

A New Source of Heterogeneity in Comparative and Translational Clinical Trials: The “Border-Time” Bias
por: Santorsola, Mariachiara, et al.
Publicado: (2022)

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR
por: Peraldo-Neia, Caterina, et al.
Publicado: (2018)

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
por: Yang, Zu-Yao, et al.
Publicado: (2012)

Lung Molecular Cytopathology: EGFR and Beyond
por: Jain, Deepali
Publicado: (2019)

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
por: Di Fiore, F, et al.
Publicado: (2010)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
por: Delaney, Christopher, et al.
Publicado: (2015)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
por: Liu, X., et al.
Publicado: (2015)

Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

EGFR Signaling in Colorectal Carcinoma
por: Krasinskas, Alyssa M.
Publicado: (2011)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u5riu8p6a7k438qkqcgjio3kf6